Although the treatment mechanism of celastrol has been reported in two NSCLC cell lines H1975 and A549 [45,46], our results further indicated a new treatment mechanism of celastrol in a selective type of EGFR survival dependent gefitinb-resistant lung cancer. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.